MENU
+Compare
CASI
Stock ticker: NASDAQ
AS OF
Jan 17 closing price
Price
$2.62
Change
+$0.12 (+4.80%)
Capitalization
40.59M

CASI CASI Pharmaceuticals Forecast, Technical & Fundamental Analysis

a developer of pharmaceutical drugs for treating cancer and inflammatory diseases

Industry Biotechnology
CASI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for CASI with price predictions
Jan 14, 2025

CASI's RSI Indicator climbs out of oversold territory

The RSI Indicator for CASI moved out of oversold territory on December 24, 2024. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 47 similar instances when the indicator left oversold territory. In of the 47 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The Moving Average Convergence Divergence (MACD) for CASI just turned positive on December 24, 2024. Looking at past instances where CASI's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where CASI advanced for three days, in of 219 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on January 10, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on CASI as a result. In of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The 50-day moving average for CASI moved below the 200-day moving average on December 24, 2024. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CASI declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for CASI entered a downward trend on January 06, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.932) is normal, around the industry mean (14.746). P/E Ratio (0.000) is within average values for comparable stocks, (87.786). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.852). CASI has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (1.651) is also within normal values, averaging (263.573).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. CASI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CASI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
CASI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

a developer of pharmaceutical drugs for treating cancer and inflammatory diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
No. 81, Jianguo Road
Phone
+86 01065618789
Employees
243
Web
https://www.casipharmaceuticals.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
BTC.X104462.0400004705.133000
+4.72%
Bitcoin cryptocurrency
TSLA426.5012.68
+3.06%
Tesla
SPY597.585.94
+1.00%
SPDR® S&P 500® ETF Trust
AAPL229.981.72
+0.75%
Apple
GME27.51-0.21
-0.76%
GameStop Corp

CASI and Stocks

Correlation & Price change

A.I.dvisor tells us that CASI and RIGL have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CASI and RIGL's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CASI
1D Price
Change %
CASI100%
+4.80%
RIGL - CASI
30%
Poorly correlated
+16.02%
ATRA - CASI
29%
Poorly correlated
-16.09%
VICP - CASI
29%
Poorly correlated
-70.71%
ADCT - CASI
27%
Poorly correlated
+4.57%
ONCO - CASI
25%
Poorly correlated
+3.37%
More